A Steadying Trajectory: Biopharma Review and Outlook

Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.

Although the pace of innovation has been strong for both pharmaceutical and biotech companies, the financing, M&A and stock market developments in the first half of 2026 for organizations in both sectors have broken from past trends in certain categories, both positively and negatively. Many of these trends would seem not to make sense on the surface, but they are logical if you carefully examine the underlying drivers.

Related to this article

Astellas secures an option on Audax’s preclinical IL-12 fusion DAX-044 in a deal worth up to $1.34 billion; EVERSANA acquires HEOR firm Estima Scientific. Credit: Stock.Adobe.com/Yingyaipumi

October 28th, 2026

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.

Enthusiasm does not equal usage: A survey of commercial leaders shows why AI uptake in pharma remains uneven and what leaders can do about it. Credit: Stock.Adobe.com/GamePixel.

October 28th, 2026

Caution and Pharma’s AI Adoption: Understanding the Reasons Behind Uneven Uptake

The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.

Teva buys BioXcel’s BXCL501 and IGALMI through a bankruptcy sale, while Rumi Therapeutics takes an option on Enthorin’s Fragile X PDE2 inhibitor. Credit: Stock.Adobe.com/bas121

October 27th, 2026

Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin

Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.

October 26th, 2026

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

October 26th, 2026

Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai

Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.

October 26th, 2026

The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki

Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

October 23rd, 2026

Building Biopharma Manufacturing for Speed, Scale, and Flexibility

Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.

October 23rd, 2026

MFN Is an Offer Pharma Can’t Refuse

Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.